Drug-Drug Interaction Study Between EDP-938, Tacrolimus, Dabigatran, Rosuvastatin and Midazolam in Healthy Subjects

Exclusion Criteria

• •Clinically relevant evidence or history of illness or disease
• •Pregnant or nursing females.
• •History of febrile illness within 7 days prior to the first dose of study drug or subjects with evidence of active infection.
• •A positive urine drug screen at Screening or Day -1.
• •Current tobacco smokers or use of tobacco within 3 months prior to Screening.
• •Any condition possibly affecting drug absorption (e.g., gastrectomy, cholecystectomy).
• •History of regular alcohol consumption.
• •Participation in a clinical trial within 30 days prior to the first dose of study drug.
• •For Part 1 subjects:
• •Clinical history or evidence at Screening consistent with hyperkalemia, hypertension and/or diabetes mellitus
• •For Part 2 Subjects:
• •Clinical history or evidence at screening of medically significant bleeding
• •History of a mechanical heart valve placement, a thromboembolic event or clinically significant thrombotic event, an autoimmune disease, eg, systemic lupus erythematosus (SLE), or recurrent spontaneous abortions
• •A platelet count \<LLN, or INR \>ULN, or aPTT \> ULN at Screening
• •Ongoing daily use of nonsteroidal anti-inflammatory drugs
• •For Part 3 subjects:
• •AST and/or ALT \>ULN at Screening
• •For Part 4 subjects:
• •History of glaucoma